CTLA4 and neoplasm: Although the mechanism is not fully understood, CTLA-4 inhibition may, as noted earlier, lower the priming threshold for new T cell activation and has been shown to increase the diversity of the T-cell receptor repertoire [41], potentially enabling a response to a greater range of tumour neoantigens.